Suchergebnisse

"The Pharmaceutical Industry: Is Pharmaceutical Research Safe and Unbiased?; Are Prescription Drugs Appropriately Regulated?; Are Pharmaceutical Marketing Practices Ethical?; Is the Cost of Prescription Drugs in America Appropriate?"--Provided by publisher

On November 4th, 2013, global health care giant Johnson & Johnson and its subsidiaries reached a settlement amount of $2.2 billion dollars. Johnson & Johnson settled to pay this amount to resolve the civil and criminal allegations of promotions not approved as safe and effective, kickbacks to physicians, and violations based on the False claim act. This type of offense has been common with pharmaceutical companies for the past ten years, but the federal government still gives pharmaceutical companies tax breaks which represent billions of dollars in lost revenue for the federal government. With this type of exemption, pharmaceutical companies are given an incentive to commit fraud for corporate greed while neglecting to put funds towards research and development.

Front Cover -- Multivariate Analysis in the Pharmaceutical Industry -- Copyright Page -- Dedication -- Contents -- List of Contributors -- About the Editors -- Foreword -- I. Background and Methodology -- 1 The Preeminence of Multivariate Data Analysis as a Statistical Data Analysis Technique in Pharmaceutical R& -- D and Manufact... -- 1.1 Data Size Glossary (Table 1.1) -- 1.2 Big Data-Overall View -- 1.3 Big Data-Pharmaceutical Context -- 1.4 Statistical Data Analysis Methods in the Pharmaceutical Industry -- 1.5 Development of Multivariate Data Analysis as a Data Analysis Technique within the Pharmaceutical Industry -- 1.6 Current Status of the Use of Multivariate Data Analysis in the Pharmaceutical Space -- 1.7 What MVA Can be Used For/What it Cannot be Used For -- 1.8 Current Limitations and Future Developments -- Acknowledgments -- References -- 2 The Philosophy and Fundamentals of Handling, Modeling, and Interpreting Large Data Sets-the Multivariate Chemometrics App... -- 2.1 Introduction -- 2.1.1 The Nature of this Chapter -- 2.1.2 The History of Metrics -- 2.2 Univariate Data and How it is Handled -- 2.2.1 Data Vectors and Some Definitions -- 2.2.2 Some Statistics on Vectors -- 2.2.3 Some General Thoughts about Univariate Thinking -- 2.3 Multivariate Data With Definitions -- 2.3.1 Data Matrices, Two-Way Arrays -- 2.3.2 Three- and More-Way Arrays -- 2.3.3 Multiblock Data -- 2.3.4 General Thoughts About Multivariate Thinking -- 2.4 Modeling -- 2.4.1 General Factor Models -- 2.4.2 Principal Component Analysis -- 2.4.3 Multivariate Curve Resolution -- 2.4.4 Clustering-Classification -- 2.4.5 Regression Models -- 2.4.6 Model Diagnostics -- 2.4.7 Some General Thoughts About Modeling -- 2.5 Conclusions -- References -- 3 Data Processing in Multivariate Analysis of Pharmaceutical Processes -- 3.1 Introduction.

S. 22-24: Pharmaceutical companies in the A.B.P.I.